The S&P hit 7,580 for its ninth consecutive winning week, and the discount rack got a little less crowded in three places: a dental distribution turnaround, a used car cycle inflection play, and a fertilizer giant sitting well below every major fair value model.

Here is where the value is and why all three deserve your attention this week.

Retail

Dollar General Corporation (NYSE: DG) trades around $110.61, against a fair value narrative of $147.39, a 25% discount, and Q1 earnings due Tuesday before the open. Wall Street is looking for $1.89 EPS on $10.83 billion in revenue. It is not cheap because the story is clean. It is cheap because investors still do not fully trust the turnaround.

Dollar General’s core shopper remains stretched, competition is aggressive, and execution still has to prove it can stabilize. But the setup is not about perfection. It is about whether margin discipline, traffic, inventory control, and full-year guidance show the bad news has already done most of its damage.

What you have here is an essential-goods retailer priced like a problem, even though one decent quarter could make the recovery story sound a lot less broken. 

Tuesday Earnings Put the Recovery Case on Trial

EPS matters, but comparable sales, gross margin, inventory, and guidance matter more. A steady print would signal to the market that Dollar General is not waiting for consumers to improve suddenly. It is fixing what it can control while the cycle stays uncomfortable.

A 25% Fair Value Gap Keeps the Risk-Reward Alive

A bruised retailer trading 25% below fair value before a next-day catalyst is exactly the kind of setup this format is built for. If Tuesday shows the consumer is holding up and execution is improving, the market may have to reprice more than one quarter.

Freight

FedEx Freight Holding Company Inc. (NYSE: FDXF), the newly separated less-than-truckload carrier from FedEx, starts life as a public company trading around $160.37 against a peer-value case of $275. That is roughly a 42% discount for North America's largest LTL carrier, with S&P 500 and Dow Jones Transportation Average inclusion already attached. 

The market has reasons to stay cautious. FDXF is fresh on the board, transition costs are real, and the freight cycle has not exactly been a party. But this is not a mystery business. FedEx Freight is targeting $8.7 billion in 2026 revenue, $1.1 billion in adjusted operating income, 4% to 6% medium-term revenue growth, and 10% to 12% operating income growth.

You are looking at a newly independent freight leader priced like the market still needs proof it can stand on its own. 

Spin-Off Unlocks a Business That Was Buried Inside FedEx

FedEx shareholders received one FDXF share for every two FedEx shares owned, while FedEx retained a 19.9% stake. That gives the company public-market focus without fully cutting the parent loose on day one.

Peer-Value Gap Makes the Setup Hard to Ignore

A $275 peer-value case is not a guaranteed target. But against a stock near $160, the gap is wide enough to matter if FDXF executes anywhere close to best-in-class LTL margins. Standalone reporting should also make it harder for the market to ignore whether this business deserves a cleaner freight multiple.

Healthcare

HealthEquity, Inc. (NASDAQ: HQY), the largest independent HSA custodian by account volume, trades around $90.50 against a $114.56 average analyst target, roughly a 21% discount. Q1 gave the market plenty to work with: revenue rose 7% to $354.6 million, net income jumped 29% to $69.4 million, adjusted EBITDA rose 17% to $164.5 million, and adjusted EBITDA margin expanded to 46%.

HealthEquity still trades around 33.9x earnings, so nobody should pretend this is being handed out for free. But the setup is not about a bargain-bin multiple. The company just raised fiscal 2027 guidance, grew total HSA assets 19% to $37.1 billion, and added $1.0 billion to its repurchase authorization.

For you, the key question is whether this profitable healthcare savings platform is finally proving that operating leverage can show up in a bigger way. 

Q1 Margin Expansion Makes the Beat Feel Bigger

A 46% adjusted EBITDA margin is not cosmetic. It tells you the HSA model is scaling while account assets keep compounding, and that gives the guidance more weight than a simple revenue beat.

$1 Billion Buyback Adds Teeth to the Valuation Case

A larger repurchase authorization matters because HealthEquity is not just talking about confidence. It is putting capital behind the idea that the stock is worth buying while the target gap remains wide.

Masco Corporation (NYSE: MAS) is a Morningstar undervalued pick selling plumbing, paint, and cabinets under Delta, Behr, and KraftMaid, and Q1 2026 confirmed the bull case is intact with plumbing revenue up 15.1% year over year and EPS beating estimates.

Housing turnover is still sitting at multi-decade lows, which means any normalization in existing home transaction volume is pure upside for pull-through demand in fixtures and finishes. The stock gained 10.6% over the past month on the back of that result and still trades below Morningstar's fair value estimate.

Management authorized a fresh buyback that continues to retire float at compressed multiples, which makes the capital return story work even while housing waits for its recovery window. The risk is that renovation and remodel spending stays depressed longer than the recovery thesis requires.

MarketAxess Holdings (NASDAQ: MKTX) runs the dominant electronic platform for institutional corporate bond trading and trades at $152 against a narrative fair value of $195.45, a 22% discount, after a 14.5% year-to-date decline that has nothing to do with the underlying business improving.

Q1 2026 revenue came in at $233.4 million, up 12% year over year, with non-GAAP EPS of $2.25, beating estimates by 4.5%, and the company completed a $300 million accelerated share repurchase. Emerging markets and Eurobond volumes grew more than 20%, showing the addressable market is expanding beyond US credit.

The buy consensus from seven analysts with a $194.71 average target tells you the discount is genuine rather than deserved. The risk is that competitive share losses to Tradeweb continue to pressure margins faster than geographic expansion can offset.

Healthpeak Properties (NYSE: DOC) is a healthcare REIT with a 7.4% dividend yield, raised 2026 guidance after Q1 FFOA of $0.45 beat estimates, and an active capital recycling program including $714 million in senior housing additions and a $312 million JV buyout with Blackstone.

The demographic tailwinds behind senior housing and medical office are structural rather than cycle-dependent, and the multiple still treats it like any other rate-sensitive REIT despite the business mix being materially better.

When the 10-year grinds sideways or lower, this is the cleanest way to capture both the income and the real estate recovery in the same position. The risk is that higher-for-longer rates keep the REIT sector compressed regardless of the underlying tenant quality.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any [blank] stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge